Medically reviewed by Dr. Mian Muhammad Sarfraz SCFHS,BLS, Pharmacovigilance Certified Pharm.D(Rph)
Updated on
💊 Pillar: Bipolar Disorder / Medications Side Effects
Bipolar Disorder Medications Side Effects : Complete Clinical Guide
Phase-specific pharmacotherapy per US FDA, EMA & UK MHRA guidance. Never discontinue mood stabilizers abruptly – rapid withdrawal ↑ relapse & suicide risk (Vieta et al., 2018).
🧪 Lithium – Gold Standard 1st Line Maintenance
▼Target Serum (TDM)
Acute mania: 0.8–1.2 mmol/L
Maintenance: 0.6–0.8 mmol/L (12h trough)
Baseline Workup
eGFR, creatinine, TSH, calcium, U&E, pregnancy test, weight, ECG if >45y
| Side Effect | Frequency | Action |
|---|---|---|
| Polyuria, polydipsia, fine tremor | Very Common | Hydration, dose timing, consider once-daily night dose |
| Hypothyroidism, weight gain | Common | TSH q6mo, diet + exercise counseling |
| eGFR decline, hypercalcemia | Monitor | Renal panel q3-6mo |
| Toxicity: coarse tremor, ataxia, confusion >1.5 mmol/L | Emergency | Hold lithium, urgent level + U&E, hydrate |
💡 Clinical Pearl: NSAIDs, ACE inhibitors, thiazides ↑ lithium. Dehydration, low salt diet & diarrhea ↑ risk. Counsel patient sick-day rules.
⚠️ Divalproex Sodium / Valproate Teratogenic Alert
▼Acute Mania Dose
20–30 mg/kg/day loading, titrated to 50–125 mcg/mL. Avoid in women of childbearing potential per MHRA.
Monitoring
LFTs, CBC, weight, BMI, menstrual history, pregnancy prevention program
| Side Effect | Frequency | Action |
|---|---|---|
| Weight gain, hair loss, tremor | Common | Dose reduction, nutritional counseling |
| Hepatotoxicity, pancreatitis, thrombocytopenia | Rare/Serious | Stop + urgent LFT/amylase/CBC |
| PCOS-like features, teratogenicity (10% major malformations) | Black Box | Contraindicated without PPP |
🚨 MHRA/EMA: Valproate banned in pregnancy for bipolar – enroll in Pregnancy Prevention Programme, annual risk acknowledgement.
🛡️ Lamotrigine – Depression Prevention No Weight Gain
▼Titration (Critical)
Wks 1-2: 25mg/day, Wks 3-4: 50mg/day, Wk5: 100mg/day, Target 200mg/day. Slower if with valproate, faster with enzyme inducers.
Why Slow?
Prevents Stevens-Johnson Syndrome. Patient card mandatory.
| Side Effect | Frequency | Action |
|---|---|---|
| Headache, insomnia, benign rash | Common | Monitor, slow titration |
| SJS/TEN, DRESS | 0.1% – Stop Immediately | ER referral, never rechallenge |
💠 Second-Generation Antipsychotics (SGAs) FDA Approved
▼| Drug – Phase | Key Side Effects | Monitoring |
|---|---|---|
| Quetiapine – Mania & Depression | Sedation, weight ↑, dyslipidemia, orthostasis | Weight, lipids, glucose, BP |
| Lurasidone, Lumateperone, Cariprazine – Depression | Nausea, akathisia (lower metabolic) | EPS scale, less metabolic but still monitor |
| Olanzapine (± Fluoxetine) – Mania/Depression | Highest weight gain, diabetes risk | HbA1c q3mo, lipids, consider metformin co-prescription |
| Aripiprazole – Mania/Maintenance | Akathisia, insomnia, impulse-control issues | Akathisia rating, impulse screening |
⚖️ Metabolic Rule: All SGAs need baseline & q3mo weight, waist, BP, fasting glucose/HbA1c, lipids per ADA/APA. Counsel on diet, exercise, smoking cessation.
📋 RxPedia TDM & Safety Checklist (Embed-ready for clinic)
☐Before Lithium: eGFR, TSH, calcium, U&E, ECG, pregnancy
☐During Lithium: Level q1wk until stable → q3mo, TSH/eGFR q6mo, weight
☐Before Valproate: LFT, CBC, weight, pregnancy test + PPP form
☐Before SGA: Weight, BMI, waist, BP, glucose, lipids, prolactin if indicated
☐Counsel: No abrupt stop, sick-day rules, hydration, avoid alcohol, suicide safety plan
References: Bipolar Medications & Side Effects
1. Lithium – Therapeutic Range & TDM
ISBD / AGNP / GERI-BD
Claim: Maintenance 0.6–0.8 mmol/L, Acute mania 0.8–1.2 mmol/L; levels <0.4 unlikely to respond.
Recent guidelines recommend lithium target maintenance 0.6 to 0.8 mmol/L【1907149477010581494†L8-L11】. Systematic review: adults should remain between 0.6 and 0.8 mmol/L, could be lowered to 0.4-0.6 in case of intolerance【1907149477010581494†L20-L23】. AGNP accepts 0.5-1.2 but maintenance advised 0.5-0.8【1907149477010581494†L20-L23】. TDM strongly recommended: 0.5–0.8 mmol/L optimal for chronic treatment【1907149477010581494†L33-L37】.
Sources: ISBD/IGSLI Task Force; AGNP Consensus; Grande et al. 2016 Lancet; GERI-BD study.
Claim: Maintenance 0.6–0.8 mmol/L, Acute mania 0.8–1.2 mmol/L; levels <0.4 unlikely to respond.
Recent guidelines recommend lithium target maintenance 0.6 to 0.8 mmol/L【1907149477010581494†L8-L11】. Systematic review: adults should remain between 0.6 and 0.8 mmol/L, could be lowered to 0.4-0.6 in case of intolerance【1907149477010581494†L20-L23】. AGNP accepts 0.5-1.2 but maintenance advised 0.5-0.8【1907149477010581494†L20-L23】. TDM strongly recommended: 0.5–0.8 mmol/L optimal for chronic treatment【1907149477010581494†L33-L37】.
Sources: ISBD/IGSLI Task Force; AGNP Consensus; Grande et al. 2016 Lancet; GERI-BD study.
2. FDA-Approved Drugs for Bipolar Depression (5 Agents)
FDA / Lancet Psychiatry
Claim: Only 5 drugs FDA-approved for acute bipolar depression: cariprazine, lumateperone, lurasidone, olanzapine-fluoxetine combo, quetiapine.
Only five pharmacological treatments (cariprazine, lumateperone, lurasidone, olanzapine–fluoxetine combination, and quetiapine) are approved by the US FDA for acute bipolar depression【3893389372144281143†L6-L9】. Multiple atypical antipsychotics are FDA approved: lurasidone, quetiapine, olanzapine-fluoxetine, cariprazine, and lumateperone【3893389372144281143†L28-L32】.
Source: The Lancet Psychiatry unmet need review; FDA labels 2021-2023.
Claim: Only 5 drugs FDA-approved for acute bipolar depression: cariprazine, lumateperone, lurasidone, olanzapine-fluoxetine combo, quetiapine.
Only five pharmacological treatments (cariprazine, lumateperone, lurasidone, olanzapine–fluoxetine combination, and quetiapine) are approved by the US FDA for acute bipolar depression【3893389372144281143†L6-L9】. Multiple atypical antipsychotics are FDA approved: lurasidone, quetiapine, olanzapine-fluoxetine, cariprazine, and lumateperone【3893389372144281143†L28-L32】.
Source: The Lancet Psychiatry unmet need review; FDA labels 2021-2023.
3. Valproate – Teratogenicity & MHRA Pregnancy Prevention Programme
MHRA / EMA / GOV.UK
Claim: 10% major birth defects, 30-40% neurodevelopmental disorders; valproate contraindicated without Pregnancy Prevention Programme (PPP).
Research shows use in pregnancy increases risk of neurodevelopmental disorders to 40%, and serious birth defects to 10%【8854796672858616475†L12-L15】. Valproate should only be used if PPP in place【8854796672858616475†L27-L31】. Valproate should not be used during pregnancy and in women of child-bearing potential unless clearly necessary【8854796672858616475†L40-L43】. MHRA introduced regulation to reduce teratogenicity【8854796672858616475†L5-L9】. Children exposed at high risk of serious developmental disorders (up to 30-40%)【8854796672858616475†L65-L68】.
Sources: MHRA Drug Safety Update Apr 2018, Jan 2024; EMA PRAC Assessment Report EMEA-H-A31-1454.
Claim: 10% major birth defects, 30-40% neurodevelopmental disorders; valproate contraindicated without Pregnancy Prevention Programme (PPP).
Research shows use in pregnancy increases risk of neurodevelopmental disorders to 40%, and serious birth defects to 10%【8854796672858616475†L12-L15】. Valproate should only be used if PPP in place【8854796672858616475†L27-L31】. Valproate should not be used during pregnancy and in women of child-bearing potential unless clearly necessary【8854796672858616475†L40-L43】. MHRA introduced regulation to reduce teratogenicity【8854796672858616475†L5-L9】. Children exposed at high risk of serious developmental disorders (up to 30-40%)【8854796672858616475†L65-L68】.
Sources: MHRA Drug Safety Update Apr 2018, Jan 2024; EMA PRAC Assessment Report EMEA-H-A31-1454.
4. Lamotrigine – Slow Titration to Prevent SJS/TEN
FDA / AAFP
Claim: 6-week titration to 200mg/day; serious rash 0.1% in bipolar trials; SJS risk ↑ with rapid titration + valproate.
Incidence of serious rash was 0.1% in all studies of bipolar disorder and included one case of mild Stevens-Johnson syndrome. Dosage titrated over 6-week period to 200 mg/day to minimise incidence【642793217053116420†L5-L8】. Should be introduced with slow dose titrations because of possibility of severe dermatological reactions, including Stevens-Johnson syndrome【642793217053116420†L24-L27】. Risk factors include rapid titration, concurrent valproic acid【642793217053116420†L35-L39】. Rate of serious rash was 0.08% (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy【642793217053116420†L42-L46】.
Source: Lamotrigine FDA PI; AAFP maintenance review.
Claim: 6-week titration to 200mg/day; serious rash 0.1% in bipolar trials; SJS risk ↑ with rapid titration + valproate.
Incidence of serious rash was 0.1% in all studies of bipolar disorder and included one case of mild Stevens-Johnson syndrome. Dosage titrated over 6-week period to 200 mg/day to minimise incidence【642793217053116420†L5-L8】. Should be introduced with slow dose titrations because of possibility of severe dermatological reactions, including Stevens-Johnson syndrome【642793217053116420†L24-L27】. Risk factors include rapid titration, concurrent valproic acid【642793217053116420†L35-L39】. Rate of serious rash was 0.08% (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy【642793217053116420†L42-L46】.
Source: Lamotrigine FDA PI; AAFP maintenance review.
5. SGAs – Metabolic Monitoring ADA/APA Consensus
ADA / APA 2004 Consensus
Claim: Baseline + ongoing monitoring: weight/BMI, waist, BP, fasting glucose, lipids for all SGAs; monthly weight, lipids/glucose at 3-4mo and annually.
Monitoring of weight or BMI, fasting plasma glucose, and fasting plasma lipids is recommended when a patient is started on a new antipsychotic, with monthly follow-up monitoring of weight/BMI, and FPG and lipid profile monitoring at three to four months and annually thereafter【4863821119448350525†L5-L9】. In 2004 ADA, APA issued consensus recommending monitoring of weight, BMI, waist circumference, and blood pressure and metabolic screening【4863821119448350525†L11-L15】. All patients receiving SGAs should receive appropriate baseline screening and ongoing monitoring【4863821119448350525†L37-L41】.
Source: ADA/APA/AACE/NAASO Consensus Statement Diabetes Care 2004.
Claim: Baseline + ongoing monitoring: weight/BMI, waist, BP, fasting glucose, lipids for all SGAs; monthly weight, lipids/glucose at 3-4mo and annually.
Monitoring of weight or BMI, fasting plasma glucose, and fasting plasma lipids is recommended when a patient is started on a new antipsychotic, with monthly follow-up monitoring of weight/BMI, and FPG and lipid profile monitoring at three to four months and annually thereafter【4863821119448350525†L5-L9】. In 2004 ADA, APA issued consensus recommending monitoring of weight, BMI, waist circumference, and blood pressure and metabolic screening【4863821119448350525†L11-L15】. All patients receiving SGAs should receive appropriate baseline screening and ongoing monitoring【4863821119448350525†L37-L41】.
Source: ADA/APA/AACE/NAASO Consensus Statement Diabetes Care 2004.
6. Do Not Stop Abruptly – Relapse Risk
Nature Reviews Disease Primers
Claim: Rapid lithium withdrawal ↑ manic relapse & suicide rebound.
Referenced in pillar: Vieta et al., 2018 – Bipolar disorders, Nature Reviews Disease Primers – clinical safety rule that mood stabilizers should never be discontinued abruptly due to elevated relapse risk. Pillar citation lines L85-L88.
Claim: Rapid lithium withdrawal ↑ manic relapse & suicide rebound.
Referenced in pillar: Vieta et al., 2018 – Bipolar disorders, Nature Reviews Disease Primers – clinical safety rule that mood stabilizers should never be discontinued abruptly due to elevated relapse risk. Pillar citation lines L85-L88.
Was this article helpful?
1 vote · Your choice helps us improve